- Co-development of rhCollagen-based dermal and soft tissue
filler products with AbbVie is advancing according to plan
- Launch of large animal study for Company's 3D bioprinted
regenerative breast implant program is on track for Q2
2022
- Initiate development of a 3D bioprinted tissue model of the
human intestine to support drug discovery and personalized medicine
for inflammatory bowel diseases in Q3 2022
- Reports strong balance sheet with cash and cash equivalents
of $41M as of March 31, 2022
REHOVOT, Israel, May 26, 2022
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:
CLGN), a regenerative and aesthetic medicine company developing
innovative technologies and products for tissue regeneration and
organ manufacturing, today announced business updates and financial
results for the first quarter ended March
31, 2022.
![CollPlant to initiate development of bioprinted intestine model CollPlant to initiate development of bioprinted intestine model](https://mma.prnewswire.com/media/1826566/CollPlant_bioprinted_intestine_model.jpg)
"CollPlant continues to make important progress executing our
internal pipeline and partnered programs, including our strategic
agreement with AbbVie to co-develop dermal and soft fillers using
our proprietary collagen technology. We believe that the
technology being developed by this collaboration could be used in
many medical applications, providing CollPlant with a significant
potential commercial opportunity," said Yehiel Tal,
CollPlant's Chief Executive Officer. "We are fortunate to have a
strong cash position, along with the potential to achieve
meaningful milestone payments, that allows us to pursue our own
development programs, including the 3D bioprinted breast implant
program, which we expect to initiate a first large animal study
this quarter. Additionally, we are gearing up for development
initiation of a 3D bioprinted tissue model that emulates the human
intestine, in Q3 2022. We believe there is a clear need for a human
based in-vitro model to support drug development and personalized
medicine applications for inflammatory bowel diseases."
"We are also exploring potential business development
opportunities arising from the recently launched Collink.3D, our
collagen-based Bioink platform that enables high fidelity
bioprinting of tissues, organs and tissue models," added Mr. Tal.
"We see growing interest in our Bioinks from academic institutions
and biopharma companies that are seeking innovative and
cost-effective solutions for drug discovery and personalized
medicine."
Recent Corporate Highlights
- 3D Bioprinted Regenerative Breast Implant Program:
CollPlant is on track to initiate a large animal study in Q2 2022
for its 3D bioprinted regenerative breast implant program, aiming
to address an estimated $2.8B market
with approximately 2.2 million procedures performed annually
worldwide. The pre-clinical study is designed to evaluate the
efficacy of bioprinted breast implants. CollPlant's regenerative
implants are designed to overcome the challenges of existing
procedures, which use silicone implants or autologous fat tissue
transfer, by slowly degrading over time to be replaced by new,
naturally grown breast tissue.
- Strategic Collaboration Agreement with AbbVie:
CollPlant's exclusive worldwide development and commercialization
agreement with AbbVie for dermal and soft tissue fillers continues
to advance. Within the framework of this collaboration, CollPlant's
proprietary rhCollagen and AbbVie's technology are combined to
develop products for the medical aesthetic market. In February 2021, CollPlant received an upfront
payment of $14 million and has the
potential to receive an additional $89
million in milestone and option payments for additional
products, which include an injectable breast implant and
photocurable dermal filler. According to the agreement, CollPlant
will also receive royalties on product sales and will manufacture
and sell rhCollagen to AbbVie.
- Collaboration Agreement with CELLINK: CollPlant signed a
collaboration agreement in February
2022 with CELLINK, a leader in 3D bioprinting technologies,
under which CELLINK's high-throughput, multi-material bioprinter is
explored for the commercial production of CollPlant's regenerative
breast implants.
- rhCollagen-based Bioinks: CollPlant recently launched
Collink.3D, a collagen-based Bioink platform, designed to support a
wide variety of 3D bioprinting applications. Collink.3D is the
first of a portfolio of Bioink products and CollPlant intends to
release two additional Bioinks in Q4 2022.
First Quarter Financial
Results
Cash, cash equivalents and short-term deposits as of March
31, 2022, were $41.1 million.
GAAP revenues for the first quarter of 2022 were $66,000
and included income from sales of the Company' BioInk and
rhCollagen. Revenues decreased by $14.4
million compared to $14.5
million in the first quarter of 2021 which mainly derived
from the $14 million upfront payment
received from AbbVie.
GAAP cost of revenue for the first quarter of 2022, was
$31,000, a decrease of 96% compared
to $886,000 in the first quarter of
2021. Cost of revenue includes mainly the cost of the Company'
rhCollagen based products, and royalties to the IIA for our sales.
The decrease in cost of revenue in the amount of approximately
$855,000 is mainly comprised of: (i)
approximately $430,000 in royalty
expenses to the IIA in 2021 mainly in relation to the AbbVie
Agreement and (ii) approximately $357,000 relating to BioInk, FG, STR and
rhCollagen sales.
GAAP gross profit for the first quarter of 2022 was $35,000, compared to gross profit of $13.6 million in the first quarter of 2021.
GAAP operating expenses for the first quarter of 2022 were
$3.8 million compared to $3.6 million in the first quarter of 2021. The
net increase of $200,000 in expenses
is mainly comprised of: (i) an increase of $303,000 in employees' salaries and share base
compensation, including recruitment of new employees for
development of new products in 3D bioprinting and medical
aesthetics, (ii) an increase of $293,000 in research and product development
activities including process development, offset by (i) a decrease
of $250,000 in general and
administrative employees salaries and directors fees and insurance
policy expenses and, (ii) a decrease of $100,000 IP expenses. On a non-GAAP basis, the
operating expenses for the first quarter of 2022 were $3.4 million compared to $3.2 million in the first quarter of 2021.
Non-GAAP measures exclude certain non-cash expenses.
GAAP financial expenses, net for the first quarter of 2022
totaled $92,000 compared to financial
income net, of $98,000 in the first
quarter of 2021. Financial expenses, net is mainly attributed to
exchange rate and income interest received from the Company's short
term cash deposit.
GAAP net loss for the first quarter of 2022 was $3.9 million or $0.36 loss per share, compared to a net income of
$10.1 million, or $1.2 basic earning per share, for the first
quarter of 2021. Non-GAAP net loss for the first quarter of 2022
was $3.5 million or $0.32 loss per share, compared to a net income of
$10.5 million, or $1.24 basic earning per share, for the
first quarter of 2021.
Cash used in operating activities during the first quarter of
2022, was $3.2 million compared to
$11.1 million cash provided by
operating activities in the first quarter of 2021. The change
is mainly attributed to the $14
million upfront payment received from AbbVie in 2021.
Cash provided by investing activities during the first quarter
of 2022, was $30 million compared to
$30.2 cash used in first quarter of
2021. The change is mainly attributed to repayment and investment
in short term cash deposits.
Cash provided by financing activities during the first quarter
of 2022, was $1.5 million compared to
cash provided by financing activities of $35.5 million in the first quarter of 2021. The
decrease is mainly attributed to the Company's registered direct
offering in February 2021, which
resulted in net proceeds of $31.8
million and a decrease of $1.3
million proceeds in exercise of warrants.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. The Company's products are based on its rhCollagen
(recombinant human collagen) produced with CollPlant's proprietary
plant based genetic engineering technology. These products address
indications for the diverse fields of tissue repair, aesthetics,
and organ manufacturing, and are ushering in a new era in
regenerative and aesthetic medicine.
At the beginning of 2021, CollPlant entered into a development
and global commercialization agreement for dermal and soft tissue
fillers with Allergan, an AbbVie company, the global leader in the
dermal filler market. Later in 2021, CollPlant entered a strategic
co-development agreement with 3D Systems for a 3D bioprinted
regenerative soft tissue matrix for use in breast reconstruction
procedures in combination with an implant.
For more information about CollPlant, visit
http://www.collplant.com
Use of Non-US GAAP ("non-GAAP")
Financial results for 2022 and 2021 are presented on both a GAAP
and a non-GAAP basis. GAAP results were prepared in accordance with
U.S. GAAP and include all revenue and expenses recognized during
the period. The release contains certain non-GAAP financial
measures for operating costs and expenses, operating income,
net income and basic and diluted net income per share that
exclude the effects of non-cash expense for fair market value
attributed to change in fair value of financial instruments,
share-based compensation to employees, directors and consultants,
and change in operating lease accounts. CollPlant's management
believes that these non-GAAP financial measures provide meaningful
supplemental information regarding the Company's performance that
enhances management's and investors' ability to evaluate the
Company's operating costs, comprehensive income and income per
share, and to compare them to historical Company results.
The presentation of this non-GAAP financial information is not
intended to be considered in isolation or as a substitute for the
financial information prepared and presented in accordance with
GAAP. Management uses both GAAP and non-GAAP measures when
operating and evaluating the Company's business internally and
therefore decided to make these non-GAAP adjustments available to
investors. The non-GAAP financial measures used by the Company in
this press release may be different from the measures used by other
companies.
For more information on the non-GAAP financial measures, please
see the "Reconciliation of GAAP to Non-GAAP Financial Measures"
later in this release. This accompanying table has more details on
the GAAP financial measures that are most directly comparable to
non-GAAP financial measures and the related reconciliations between
these financial measures.
The Company's consolidated financial results for the first three
months ended March 31, 2022, are
presented in accordance with generally accepted accounting
principles in the United States of
America.
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the impact of the COVID-19
pandemic; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk and products for
medical aesthetics; the Company's ability to obtain favorable
pre-clinical and clinical trial results; regulatory action with
respect to rhCollagen based BioInk and medical aesthetics products
including but not limited to acceptance of an application for
marketing authorization review and approval of such application,
and, if approved, the scope of the approved indication and
labeling; commercial success and market acceptance of the Company's
rhCollagen based products in 3D Bioprinting and medical aesthetics;
the Company's ability to establish sales and marketing capabilities
or enter into agreements with third parties and its reliance on
third party distributors and resellers; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the Company's reliance on third parties to conduct
some or all aspects of its product manufacturing; the scope of
protection the Company is able to establish and maintain for
intellectual property rights and the Company's ability to operate
its business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the Company operates;
projected capital expenditures and liquidity; changes in the
Company's strategy; and litigation and regulatory proceedings. More
detailed information about the risks and uncertainties affecting
CollPlant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the
SEC, and in other filings that CollPlant has made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's current views with respect to future
events, and CollPlant does not undertake and specifically disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
COLLPLANT
BIOTECHNOLOGIES LTD.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(U.S. dollars in
thousands)
|
|
|
|
|
|
|
|
March 31,
2022
|
|
|
December 31,
2021
|
Assets
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
|
$
|
41,072
|
|
|
$
|
13,148
|
Short term cash
deposits
|
|
|
|
-
|
|
|
|
30,151
|
Restricted
deposit
|
|
|
|
13
|
|
|
|
13
|
Trade
receivables
|
|
|
|
-
|
|
|
|
270
|
Other accounts
receivable and prepaid expenses
|
|
|
|
263
|
|
|
|
424
|
Inventories
|
|
|
|
1,267
|
|
|
|
1,081
|
Total current
assets
|
|
|
|
42,615
|
|
|
|
45,087
|
Non-current
assets:
|
|
|
|
|
|
|
|
|
Restricted
deposit
|
|
|
|
208
|
|
|
|
213
|
Operating lease
right-of-use assets
|
|
|
|
2,867
|
|
|
|
2,953
|
Property and equipment,
net
|
|
|
|
2,794
|
|
|
|
2,728
|
Intangible assets,
net
|
|
|
|
239
|
|
|
|
243
|
Total non-current
assets
|
|
|
|
6,108
|
|
|
|
6,137
|
Total
assets
|
|
|
$
|
48,723
|
|
|
$
|
51,224
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
|
|
(U.S. dollars in
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2022
|
|
|
December 31,
2021
|
|
|
Liabilities and
shareholders' equity
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
Trade payables
|
|
|
$
|
1,003
|
|
|
$
|
1,034
|
|
|
Operating lease
liabilities
|
|
|
|
513
|
|
|
|
519
|
|
|
Deferred revenues
|
|
|
|
-
|
|
|
|
32
|
|
|
Accrued liabilities and other
|
|
|
|
1,096
|
|
|
|
1,429
|
|
|
Total
current liabilities
|
|
|
|
2,612
|
|
|
|
3,014
|
|
|
Non-current
liabilities:
|
|
|
|
|
|
|
|
|
|
|
Operating lease liabilities
|
|
|
|
2,915
|
|
|
|
3,089
|
|
|
Total non-current
liabilities
|
|
|
|
2,915
|
|
|
|
3,089
|
|
|
Total
liabilities
|
|
|
|
5,527
|
|
|
|
6,103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders'
Equity:
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares, NIS 1.5 par value -
authorized: 30,000,000 ordinary
shares as of
March 31, 2022 and December 31, 2021; issued and
outstanding:
11,086,481 and 10,772,024 ordinary shares as of
March 31,
2022 and December 31, 2021, respectively
|
|
|
|
4,831
|
|
|
|
4,664
|
|
|
Additional paid in capital
|
|
|
|
115,991
|
|
|
|
114,223
|
|
|
Currency translation differences
|
|
|
|
(969)
|
|
|
|
(969)
|
|
|
Accumulated deficit
|
|
|
|
(76,657)
|
|
|
|
(72,797)
|
|
|
Total shareholders'
equity
|
|
|
|
43,196
|
|
|
|
45,121
|
|
|
Total liabilities
and shareholders' equity
|
|
|
$
|
48,723
|
|
|
$
|
51,224
|
|
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
(U.S. dollars in
thousands, except share and per share data)
|
|
|
|
|
|
|
Three months
ended
March 31,
|
|
|
|
|
|
2022
|
|
|
2021
|
Revenues
|
|
|
|
|
|
$
|
66
|
|
|
$
|
14,500
|
Cost of
revenues
|
|
|
|
|
|
|
31
|
|
|
|
886
|
Gross
Profit
|
|
|
|
|
|
|
35
|
|
|
|
13,614
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
|
|
|
|
|
2,242
|
|
|
|
1,633
|
General, administrative
and marketing
|
|
|
|
|
|
|
1,561
|
|
|
|
1,955
|
Total operating
income (loss)
|
|
|
|
|
|
|
(3,768)
|
|
|
|
10,026
|
Financial income
(expenses), net
|
|
|
|
|
|
|
(92)
|
|
|
|
98
|
Net income (loss)
|
|
|
|
|
|
$
|
(3,860)
|
|
|
$
|
10,124
|
Basic net income
(loss) per ordinary share
|
|
|
|
|
|
|
(0.36)
|
|
|
|
1.2
|
Diluted net income
(loss) per ordinary share
|
|
|
|
|
|
|
(0.36)
|
|
|
|
0.88
|
Weighted average
ordinary shares outstanding used in
computation of basic net income (loss) per
share
|
|
|
|
|
|
|
10,783,065
|
|
|
|
8,413,725
|
Weighted average
ordinary shares outstanding used in
computation of diluted net income (loss) per
share
|
|
|
|
|
|
|
10,783,065
|
|
|
|
11,481,163
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(U.S. dollars in
thousands)
|
|
|
|
|
|
Three months
ended
March 31,
|
|
|
|
2022
|
|
|
2021
|
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
Income (loss)
|
|
$
|
(3,860)
|
|
|
$
|
10,124
|
|
|
Adjustments for:
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
240
|
|
|
|
173
|
|
|
Gains from Short term cash deposits
|
|
|
(36)
|
|
|
|
(16)
|
|
|
Share-based compensation to employees and
consultants
|
|
|
461
|
|
|
|
485
|
|
|
Exchange differences on cash and cash equivalents
|
|
|
228
|
|
|
|
68
|
|
|
Financial expenses (income) related to financial
instruments
|
|
|
|
|
|
|
(28)
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in operating asset and liability items:
|
|
|
|
|
|
|
|
|
|
Decrease in trade receivables
|
|
|
270
|
|
|
|
656
|
|
|
Increase in inventories
|
|
|
(186)
|
|
|
|
(13)
|
|
|
Decrease (increase) in other receivables
|
|
|
161
|
|
|
|
(28)
|
|
|
Decrease in operating right of use assets
|
|
|
110
|
|
|
|
103
|
|
|
Increase (decrease) in trade payables
|
|
|
(31)
|
|
|
|
96
|
|
|
Decrease in lease liabilities
|
|
|
(204)
|
|
|
|
(230)
|
|
|
Decrease in accrued liabilities and other
payables
|
|
|
(333)
|
|
|
|
(229)
|
|
|
Decrease in deferred revenues
|
|
|
(32)
|
|
|
|
(43)
|
|
|
Net
cash provided by (used in) operating activities
|
|
|
(3,212)
|
|
|
|
11,118
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
|
Capitalization of intangible assets
|
|
|
(6)
|
|
|
|
(56)
|
|
|
Purchase of property and equipment
|
|
|
(296)
|
|
|
|
(123)
|
|
|
Repayment of short
term deposits
|
|
|
30,187
|
|
|
|
-
|
|
|
Investment in short term deposits
|
|
|
-
|
|
|
|
(30,000)
|
|
|
Net
cash provided by (used in) investing activities
|
|
|
29,885
|
|
|
|
(30,179)
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of shares and warrants less issuance
expenses
|
|
|
-
|
|
|
|
32,743
|
|
|
Exercise of options and warrants into shares
|
|
|
1,474
|
|
|
|
2,770
|
|
|
Net
cash provided by financing activities
|
|
|
1,474
|
|
|
|
35,513
|
|
|
Increase in cash and
cash equivalents and restricted deposits
|
|
|
28,147
|
|
|
|
16,452
|
|
|
Cash and cash
equivalents and restricted deposits at the beginning of the
year
|
|
|
13,374
|
|
|
|
3,526
|
|
|
Exchange differences
on cash and cash equivalents and restricted
deposits
|
|
|
(228)
|
|
|
|
(68)
|
|
|
Cash and cash
equivalents and restricted deposits at the end of the
year
|
|
$
|
41,293
|
|
|
$
|
19,910
|
|
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
APPENDICES TO
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(U.S. dollars in
thousands)
|
|
|
|
|
|
Three months
ended
March 31,
|
|
|
|
2022
|
|
|
2021
|
|
Appendix to the
statement of cash flows
|
|
|
|
|
|
|
A. Supplementary
information on investing and financing
activities not involving cash flows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Obtaining right of use
assets in exchange for a lease liability
|
|
|
24
|
|
|
|
105
|
|
Classification of
issuance costs liability to equity
|
|
|
-
|
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
B. Reconciliation of
Cash, cash equivalents and restricted cash
at the end of the year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
|
41,072
|
|
|
|
19,724
|
|
Restricted deposits
(including long term)
|
|
|
221
|
|
|
|
186
|
|
Total cash and cash
equivalents and restricted deposits
|
|
$
|
41,293
|
|
|
$
|
19,910
|
|
CollPlant
Biotechnologies Ltd.
|
|
Reconciliation of
GAAP to Non-GAAP Financial Measures
|
|
(U.S. dollars in
thousands, except per share data)
|
|
(Unaudited)
|
|
|
|
|
|
Three months
ended
March 31,
|
|
|
|
2022
|
|
|
2021
|
|
|
|
USD in
thousands
|
|
|
|
|
|
|
|
GAAP
gross profit
|
|
$
|
35
|
|
|
$
|
13,614
|
|
|
|
|
|
|
|
|
|
|
GAAP operating costs
and expenses:
|
|
|
3,803
|
|
|
|
3,588
|
|
|
|
|
|
|
|
|
|
|
Change of operating lease accounts
|
|
|
94
|
|
|
|
127
|
|
Share-based compensation to employees, directors and
consultants
|
|
|
(461)
|
|
|
|
(485)
|
|
Non-GAAP operating
costs and expenses:
|
|
|
3,436
|
|
|
|
3,230
|
|
|
|
|
|
|
|
|
|
|
GAAP operating income (loss)
|
|
|
(3,768)
|
|
|
|
10,026
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP operating income (loss)
|
|
|
(3,401)
|
|
|
|
10,384
|
|
|
|
|
|
|
|
|
|
|
GAAP net income (loss)
|
|
|
(3,860)
|
|
|
|
10,124
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of financial instruments
|
|
|
-
|
|
|
|
(28)
|
|
Change of operating lease accounts
|
|
|
(94)
|
|
|
|
(127)
|
|
Share-based compensation to employees, directors and
consultants
|
|
|
461
|
|
|
|
485
|
|
Non-GAAP net income (loss)
|
|
$
|
(3,493)
|
|
|
$
|
10,454
|
|
GAAP Basic net income (loss) per ordinary
share
|
|
$
|
(0.36)
|
|
|
$
|
1.2
|
|
GAAP diluted net income (loss) per ordinary
share
|
|
|
(0.36)
|
|
|
|
0.88
|
|
Non-GAAP Basic net income (loss) per ordinary
share
|
|
$
|
(0.32)
|
|
|
$
|
1.24
|
|
Non-GAAP diluted net income (loss) per ordinary
share
|
|
|
(0.32)
|
|
|
|
0.91
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/collplant-biotechnologies-provides-business-updates-and-first-quarter-2022-financial-results-301555703.html
SOURCE CollPlant